Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study

Share this Article

Singapore Med J 2014; 55(7): 378-382; http://dx.doi.org/10.11622/smedj.2014090
Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study

Hung TH, Tsai CC, Tsai CC, Tseng CW, Hsieh YH
Correspondence:  Dr Yu-Hsi Hsieh, hsieh.yuhsi@msa.hinet.net

ABSTRACT
INTRODUCTION Necrotising fasciitis (NF) is often found in patients with diabetes mellitus, chronic renal failure, alcoholism, malignancy or liver cirrhosis. However, it remains unknown whether liver cirrhosis is an independent risk factor for the occurrence of NF. This study aimed to determine whether liver cirrhosis is an independent risk factor for the occurrence of NF, and to identify the relationship between severity of liver cirrhosis and occurrence of NF.
METHODS The National Health Insurance Research Database, maintained by Taiwan’s National Health Insurance programme, was retrospectively analysed, and the hospitalisation data of 40,802 cirrhotic patients and 40,865 randomly selected, age? and gender?matched non?cirrhotic control patients was collected. The medical records of all patients were individually followed for a three?year period from the patients’ first hospitalisation in 2004.
RESULTS During the three?year follow?up period, there were 299 (0.7%) cirrhotic patients with NF and 160 (0.4%) non?cirrhotic patients with NF. Cox regression analysis showed that liver cirrhosis was a risk factor for the occurrence of NF during the study period (hazard ratio 1.982; p < 0.001). Among cirrhotic patients, those with complicated liver cirrhosis had a higher risk for the occurrence of NF than patients with non?complicated liver cirrhosis (hazard ratio 1.320; p = 0.028).
CONCLUSION Cirrhotic patients had a higher risk for the occurrence of NF than non?cirrhotic patients, and the risk for NF was especially high among patients with complicated liver cirrhosis.

Keywords: cirrhosis, complicated liver cirrhosis, necrotising fasciitis
Singapore Med J 2014; 55(7): 378-382; http://dx.doi.org/10.11622/smedj.2014090

REFERENCES

1. Anaya DA, McMahon K, Nathens AB, et al. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005; 140:151?7.
http://dx.doi.org/10.1001/archsurg.140.2.151
 
2. Lee CC, Chi CH, Lee NY, et al. Necrotizing fasciitis in patients with liver cirrhosis: predominance of monomicrobial Gram?negative bacillary infections. Diagn Microbiol Infect Dis 2008; 62:219?25.
http://dx.doi.org/10.1016/j.diagmicrobio.2008.05.016
 
3. Huang KF, Hung MH, Lin YS, et al. Independent predictors of mortality for necrotizing fasciitis: a retrospective analysis in a single institution. J Trauma 2011; 71:467?73.
http://dx.doi.org/10.1097/TA.0b013e318220d7fa
 
4. Bair MJ, Chi H, Wang WS, et al. Necrotizing fasciitis in southeast Taiwan: clinical features, microbiology, and prognosis. Int J Infect Dis 2009; 13:255?60.
http://dx.doi.org/10.1016/j.ijid.2008.04.015
 
5. Christou L, Pappas G, Falagas ME. Bacterial infection?related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007; 102:1510?7.
http://dx.doi.org/10.1111/j.1572-0241.2007.01286.x
 
6. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140?8.
http://dx.doi.org/10.1053/jhep.2002.30082
 
7. Cheng NC, Tai HC, Tang YB, et al. Necrotising fasciitis: clinical features in patients with liver cirrhosis. Br J Plast Surg 2005; 58:702?7.
http://dx.doi.org/10.1016/j.bjps.2005.01.019
 
8. Hung CC, Chang SC, Lin SF, et al. Clinical manifestations, microbiology and prognosis of 42 patients with necrotizing fasciitis. J Formos Med Assoc 1996; 95:917?22.
PMid:9000808
 
9. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40:381?7.
http://dx.doi.org/10.1038/sj.bmt.1705727
 
10. O'Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995?1999. Clin Infect Dis 2002; 35:268?76.
http://dx.doi.org/10.1086/341409
 
11. Kaul R, McGeer A, Low DE, et al. Population?based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy?seven cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103:18?24.
http://dx.doi.org/10.1016/S0002-9343(97)00160-5
 
12. Baxter F, McChesney J. Severe group A streptococcal infection and streptococcal toxic shock syndrome. Can J Anaesth 2000; 47:1129?40.
http://dx.doi.org/10.1007/BF03027968
 
13. Eneli I, Davies HD. Epidemiology and outcome of necrotizing fasciitis in children: an active surveillance study of the Canadian Paediatric Surveillance Program. J Pediatr 2007; 151:79?84.
http://dx.doi.org/10.1016/j.jpeds.2007.02.019
 
14. Hsu HC, Lin WS, Tsai MJ. Hepatitis?B surface antigen and hepatocellular carcinoma in Taiwan. With special reference to types and localization of HBsAg in the tumor cells. Cancer 1983; 52:1825?32.
http://dx.doi.org/10.1002/1097-0142(19831115)52:10<1825::AID-CNCR2820521011>3.0.CO;2-M
 
15. Tsai JF, Chang WY, Jeng JE, et al. Hepatitis C virus infection as a risk factor for non?alcoholic liver cirrhosis in Taiwan. J Med Virol 1993; 41:296?300.
http://dx.doi.org/10.1002/jmv.1890410407
 
16. Wong CH, Chang HC, Pasupathy S, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85?A:1454?60.
 
17. Lin C, Yeh FL, Lin JT, et al. Necrotizing fasciitis of the head and neck: an analysis of 47 cases. Plast Reconstr Surg 2001; 107:1684?93.
http://dx.doi.org/10.1097/00006534-200106000-00008
 
18. Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest 1996; 110:219?29.
http://dx.doi.org/10.1378/chest.110.1.219
 
19. McHenry CR, Piotrowski JJ, Petrinic D, et al. Determinants of mortality for necrotizing soft?tissue infections. Ann Surg 1995; 221:558?63.
http://dx.doi.org/10.1097/00000658-199505000-00013
 
20. Shimizu T, Tokuda Y. Necrotizing fasciitis. Intern Med 2010; 49:1051?7.
http://dx.doi.org/10.2169/internalmedicine.49.2964
 
21. Mulla ZD. Streptococcal myositis. Br J Plast Surg 2003; 56:424.
http://dx.doi.org/10.1016/S0007-1226(03)00129-2
 
22. Childers BJ, Potyondy LD, Nachreiner R, et al. Necrotizing fasciitis: a fourteen?year retrospective study of 163 consecutive patients. Am Surg 2002; 68:109?16.
PMid:11842952
 
23. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 1996; 224:672?83.
http://dx.doi.org/10.1097/00000658-199611000-00011
 
24. Lamagni TL, Darenberg J, Luca?Harari B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008; 46:2359?67.
http://dx.doi.org/10.1128/JCM.00422-08
 
25. Murphy JJ, Granger R, Blair GK, et al. Necrotizing fasciitis in childhood. J Pediatr Surg 1995; 30:1131?4.
http://dx.doi.org/10.1016/0022-3468(95)90004-7
 
26. Nuwayhid ZB, Aronoff DM, Mulla ZD. Blunt trauma as a risk factor for group A streptococcal necrotizing fasciitis. Ann Epidemiol 2007; 17:878?81.
http://dx.doi.org/10.1016/j.annepidem.2007.05.011
 
27. Headley AJ. Necrotizing soft tissue infections: a primary care review. Am Fam Physician 2003; 68:323?8.
PMid:12892352
 
28. Garcia?Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18:353?72.
http://dx.doi.org/10.1016/j.bpg.2003.10.005
 
29. Galati JS, Holdeman KP, Bottjen PL, et al. Gastric emptying and orocecal transit in portal hypertension and end?stage chronic liver disease. Liver Transpl Surg 1997; 3:34?8.
http://dx.doi.org/10.1002/lt.500030105
 
30. Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003; 98:1362?70.
http://dx.doi.org/10.1111/j.1572-0241.2003.07475.x
 
31. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45:744?57.
http://dx.doi.org/10.1016/j.jhep.2006.08.001
 
32. Wiest R, Garcia?Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:422?33.
http://dx.doi.org/10.1002/hep.20632
 
33. Fierer J, Finley F. Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver. J Clin Invest 1979; 63:912?21.
http://dx.doi.org/10.1172/JCI109391
 
34. Garcia?González M, Boixeda D, Herrero D, et al. Effect of granulocyte?macrophage colony?stimulating factor on leukocyte function in cirrhosis. Gastroenterology 1993; 105:527?31.
 
35. Mellencamp MA, Preheim LC. Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae. J Infect Dis 1991; 163:102?8.
http://dx.doi.org/10.1093/infdis/163.1.102
 
36. Homann C, Varming K, Høgåsen K, et al. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997; 40:544?9.
PMid:9176087 PMCid:PMC1027133
 
37. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4:53?8.
http://dx.doi.org/10.1002/hep.1840040109
 
38. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33:41?8.
http://dx.doi.org/10.1016/S1590-8658(01)80134-1
 
39. Thulstrup AM, Sørensen HT, Schønheyder HC, et al. Population?based study of the risk and short?term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000; 31:1357?61.
http://dx.doi.org/10.1086/317494
 
40. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124:1016?20.
http://dx.doi.org/10.1378/chest.124.3.1016
 
41. Kuo CH, Changchien CS, Yang CY, et al. Bacteremia in patients with cirrhosis of the liver. Liver 1991; 11:334?9.
http://dx.doi.org/10.1111/j.1600-0676.1991.tb00539.x

Immunosuppressant dose reduction and long-term rejection risk in renal transplant recipients with severe bacterial pneumonia

Share this Article

Singapore Med J 2014; 55(7): 372-377; http://dx.doi.org/10.11622/smedj.2014089
Immunosuppressant dose reduction and long-term rejection risk in renal transplant recipients with severe bacterial pneumonia

Shih CJ, Tarng DC, Yang WC, Yang CY
Correspondence: Dr Chih-Yu Yang, cyyang3@vghtpe.gov.tw

ABSTRACT
INTRODUCTION Due to lifelong immunosuppression, renal transplant recipients (RTRs) are at risk of infectious complications such as pneumonia. Severe pneumonia results in respiratory failure and is life?threatening. We aimed to examine the influence of immunosuppressant dose reduction on RTRs with bacterial pneumonia and respiratory failure.
METHODS From January 2001 to January 2011, 33 of 1,146 RTRs at a single centre developed bacterial pneumonia with respiratory failure. All patients were treated using mechanical ventilation and aggressive therapies in the intensive care unit.
RESULTS Average time from kidney transplantation to pneumonia with respiratory failure was 6.8 years. In-hospital mortality rate was 45.5% despite intensive care and aggressive therapies. Logistic regression analysis indicated that a high serum creatinine level at the time of admission to the intensive care unit (odds ratio 1.77 per mg/dL, 95% confidence interval 1.01–3.09; p = 0.045) was a mortality determinant. Out of the 33 patients, immunosuppressive agents were reduced in 17 (51.5%). We found that although immunosuppressant dose reduction tended to improve in-hospital mortality, this was not statistically significant. Nevertheless, during a mean follow-up period of two years, none of the survivors (n = 18) developed acute rejection or allograft necrosis.
CONCLUSION In RTRs with bacterial pneumonia and respiratory failure, higher serum creatinine levels were a mortality determinant. Although temporary immunosuppressant dose reduction might not reduce mortality, it was associated with a minimal risk of acute rejection during the two-year follow-up. Our results suggest that early immunosuppressant reduction in RTRs with severe pneumonia of indeterminate microbiology may be safe even when pathogens are bacterial in nature.

Keywords: immunosuppressant, kidney transplant, mortality, pneumonia, respiratory failure
Singapore Med J 2014; 55(7): 372-377; http://dx.doi.org/10.11622/smedj.2014089

REFERENCES

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-30.
http://dx.doi.org/10.1056/NEJM199912023412303
 
2. Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11:917-22.
PMid:10770970
 
3. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14.
http://dx.doi.org/10.1056/NEJMra064928
 
4. Washer GF, Schroter GP, Starzl TE, Weil R, 3rd. Causes of death after kidney transplantation. JAMA 1983; 250:49-54.
http://dx.doi.org/10.1001/jama.1983.03340010031024
 
5. Candan S, Pirat A, Varol G, et al. Respiratory problems in renal transplant recipients admitted to intensive care during long-term follow-up. Transplant Proc 2006; 38:1354-6.
http://dx.doi.org/10.1016/j.transproceed.2006.02.083
 
6. Hoyo I, Linares L, Cervera C, et al. Epidemiology of pneumonia in kidney transplantation. Transplant Proc 2010; 42:2938-40.
http://dx.doi.org/10.1016/j.transproceed.2010.07.082
 
7. Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12:397-405.
http://dx.doi.org/10.1111/j.1399-3062.2010.00526.x
 
8. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77:299-311.
http://dx.doi.org/10.1038/ki.2009.377
 
9. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
http://dx.doi.org/10.1164/rccm.200405-644ST
 
10. Mandell LA, Wunderink RG, Anzueto A, Bar, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27-72.
http://dx.doi.org/10.1086/511159
 
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
http://dx.doi.org/10.1097/00003246-198510000-00009
 
12. British Thoracic Society Standards of Care C. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 Suppl 4:IV1-64.
http://dx.doi.org/10.1136/thx.56.suppl_4.iv1
 
13. Canet E, Osman D, Lambert J, et al. Acute respiratory failure in kidney transplant recipients: a multicenter study. Crit Care 2011; 15:R91.
http://dx.doi.org/10.1186/cc10091
 
14. James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24-32.
http://dx.doi.org/10.1053/j.ajkd.2009.04.005
 
15. Viasus D, Garcia-Vidal C, Cruzado JM, et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26:2899-906.
http://dx.doi.org/10.1093/ndt/gfq798
 
16. Kasiske BL, Israni AK, Snyder JJ, Skeans MA. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011; 57:466-75.
http://dx.doi.org/10.1053/j.ajkd.2010.10.054
 
17. Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 2011; 26:2013-7.
http://dx.doi.org/10.1093/ndt/gfq689
 
18. Aldawood A. The course and outcome of renal transplant recipients admitted to the intensive care unit at a tertiary hospital in Saudi Arabia. Saudi J Kidney Dis Transpl 2007; 18:536-40.
PMid:17951939
 
19. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307-13.
http://dx.doi.org/10.1046/j.1523-1755.2000.00816.x
 
20. Stamm AM. Infection in organ-transplant recipients. N Engl J Med 1998; 339:1246.
PMid:9786757
 
21. Lindemann M, Heinemann FM, Horn PA, Witzke O. Immunity to pneumococcal antigens in kidney transplant recipients. Transplantation 2010; 90:1463-7.
http://dx.doi.org/10.1097/TP.0b013e3181f5d878
 
22. Etienne I, Toupance O, Benichou J, et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrol Dial Transplant 2010; 25:3096-106.
http://dx.doi.org/10.1093/ndt/gfq135
 
23. Watorek E, Szymczak M, Boratynska M, Patrzalek D, Klinger M. Cardiovascular risk in kidney transplant recipients receiving Mammalian target of rapamycin inhibitors. Transplant Proc 2011; 43:2967-9.
http://dx.doi.org/10.1016/j.transproceed.2011.08.009
 
24. Luan FL, Steffick DE, Ojo AO. Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int 2009; 76:825-30.
http://dx.doi.org/10.1038/ki.2009.248
 
25. Sileri P, Pursell KJ, Coady NT, et al. A standardized protocol for the treatment of severe pneumonia in kidney transplant recipients. Clin Transplant 2002; 16:450-4.
http://dx.doi.org/10.1034/j.1399-0012.2002.02079.x
 
26. van de Wetering J, van der Mast BJ, de Kuiper P, et al. Reduction of immunosuppressive load in renal transplant recipients with a low donor-specific cytotoxic T-lymphocyte precursor frequency is safe. Transplant Proc 2005; 37:779-81.
http://dx.doi.org/10.1016/j.transproceed.2004.11.061
 
27. Li SH, Wang W, Hu XP, et al. Monitoring immune function after rapid corticosteroid reduction in kidney transplant recipients. Chin Med J (Engl) 2011; 124:679-82.
 
28. Klouche K, Amigues L, Massanet P, et al. Outcome of renal transplant recipients admitted to an intensive care unit: a 10-year cohort study. Transplantation 2009; 87:889-95.
http://dx.doi.org/10.1097/TP.0b013e31819a688a
 
29. Kirilov D, Cohen J, Shapiro M, Grozovski E, Singer P. The course and outcome of renal transplant recipients admitted to a general intensive care unit. Transplant Proc 2003; 35:606.
http://dx.doi.org/10.1016/S0041-1345(03)00007-1
 
30. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2:970-4.
http://dx.doi.org/10.1034/j.1600-6143.2002.21015.x
 
31. Polverino E, Torres A. Current perspective of the HCAP problem: is it CAP or is it HAP? Semin Respir Crit Care Med 2009; 30:239-48.
http://dx.doi.org/10.1055/s-0029-1202940

Detection of Strongyloides stercoralis infection among cancer patients in a major hospital in Kelantan, Malaysia

Share this Article

Singapore Med J 2014; 55(7): 367-371; http://dx.doi.org/10.11622/smedj.2014088
Detection of Strongyloides stercoralis infection among cancer patients in a major hospital in Kelantan, Malaysia

Zueter AM, Mohamed Z, Abdullah AD, Mohamad N, Arifin N, Othman N, Noordin R
Correspondence: Dr Rahmah Noordin, rahmah8485@gmail.com

ABSTRACT
INTRODUCTION Strongyloidiasis is one of the most commonly neglected but clinically important parasitic infections worldwide, especially among immunocompromised patients. Evidence of infection among immunocompromised patients in Malaysia is, however, lacking. In this study, microscopy, real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assays (ELISAs) were used to detect Strongyloides stercoralis (S. stercoralis) infection among cancer patients in a Malaysian hospital.
METHODS A total of 192 stool and serum samples were collected from cancer patients who were receiving chemotherapy with or without steroid treatment at a hospital in northeastern Malaysia. Stool samples were examined for S. stercoralis using parasitological methods and real-time PCR. Serology by ELISA was performed to detect parasite-specific immunoglobulin G (IgG), IgG4 and immunoglobulin E (IgE) antibodies. For comparison, IgG4- and IgG-ELISAs were also performed on the sera of 150 healthy individuals from the same area.
RESULTS Of the 192 samples examined, 1 (0.5%) sample was positive for S. stercoralis by microscopy, 3 (1.6%) by real-time PCR, 8 (4.2%) by IgG-ELISA, 6 (3.1%) by IgG4-ELISA, and none was positive by IgE-ELISA. In comparison, healthy blood donors had significantly lower prevalence of parasite-specific IgG (2.67%, p < 0.05) and IgG4 (2.67%, p < 0.05) responses.
CONCLUSION This study showed that laboratory testing may be considered as a diagnostic investigation for S. stercoralis among immunocompromised cancer patients.

Keywords: cancer patients, ELISAs, microscopy, real-time PCR, Strongyloides stercoralis
Singapore Med J 2014; 55(7): 367-371; http://dx.doi.org/10.11622/smedj.2014088

REFERENCES

1. Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis 1989; 11:755-67.
http://dx.doi.org/10.1093/clinids/11.5.755
 
2. Douce RW, Brown AE, Khamboonruang C, Walzer PD, Genta RM. Seroepidemiology of strongyloidiasis in a Thai village. Int J Parasitol 1987; 17:1343-8.
http://dx.doi.org/10.1016/0020-7519(87)90101-9
 
3. Schaffel R, Nucci M, Carvalho E, et al. The value of an immunoenzymatic test (enzyme-linked immunosorbent assay) for the diagnosis of strongyloidiasis in patients immunosuppressed by hematologic malignancies. Am J Trop Med Hyg 2001; 65:346-50.
PMid:11693882
 
4. Daubenton JD, Buys HA,Hartley PS. Disseminated strongyloidiasis in a child with lymphoblastic lymphoma. J Pediatr Hematol Oncol 1998; 20:260-3.
http://dx.doi.org/10.1097/00043426-199805000-00014
 
5. Ganesh S, Cruz RJ, Jr. Strongyloidiasis: a multifaceted disease. Gastroenterol Hepatol (NY) 2011; 7:194-6.
 
6. Marcos LA, Terashima A, Canales M, Gotuzzo E. Update on strongyloidiasis in the immunocompromised host. Curr Infect Dis Rep 2011; 13:35-46.
http://dx.doi.org/10.1007/s11908-010-0150-z
 
7. Olsen A, van Lieshout L, Marti H, et al. Strongyloidiasis-the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg 2009; 103:967-72.
http://dx.doi.org/10.1016/j.trstmh.2009.02.013
 
8. Basuni M, Muhi J, Othman N, et al. A pentaplex real-time polymerase chain reaction assay for detection of four species of soil-transmitted helminths. Am J Trop Med Hyg 2011; 84:338-43.
http://dx.doi.org/10.4269/ajtmh.2011.10-0499
 
9. van Doorn HR, Koelewijn R, Hofwegen H, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45:438-42.
http://dx.doi.org/10.1128/JCM.01735-06
 
10. Verweij JJ, Canales M, Polman K, et al. Molecular diagnosis of Strongyloides stercoralis in faecal samples using real-time PCR. Trans R Soc Trop Med Hyg 2009; 103:342-6.
http://dx.doi.org/10.1016/j.trstmh.2008.12.001
 
11. Hutchison RE, Schexneider KI. Leukocytic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. Philadelphia: Saunders Elsevier, 2011.
http://dx.doi.org/10.1016/B978-1-4377-0974-2.00033-6
 
12. Norsyahida A, Riazi M, Sadjjadi SM, et al. Laboratory detection of strongyloidiasis: IgG, IgG4- and IgE ELISAs and cross-reactivity with lymphatic filariasis. Parasite Immunol 2013; 35:174-9.
http://dx.doi.org/10.1111/pim.12029
 
13. Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:143-8.
http://dx.doi.org/10.1111/j.1399-3062.2008.00360.x
 
14. Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004; 17:208-17.
http://dx.doi.org/10.1128/CMR.17.1.208-217.2004
 
15. Janwan P, Intapan PM, Thanchomnang T, et al. Rapid detection of Opisthorchis viverrini and Strongyloides stercoralis in human fecal samples using a duplex real-time PCR and melting curve analysis. Parasitol Res 2011; 109:1593-601.
http://dx.doi.org/10.1007/s00436-011-2419-z
 
16. Ten Hove R, Van Esbroeck M, Vervoort T, et al. Molecular diagnostics of intestinal parasites in returning travellers. Eur J Clin Microbiol Infect Dis 2009; 28:1045-53.
http://dx.doi.org/10.1007/s10096-009-0745-1
 
17. Basuni M, Mohamed Z, Ahmad M, Zakaria NZ, Noordin R. Detection of selected intestinal helminths and protozoa at Hospital Universiti Sains Malaysia using multiplex real-time PCR. Trop Biomed 2012; 29:434-42.
PMid:23018507
 
18. Kia EB, Rahimi HR, Mirhendi H, et al. A case of fatal strongyloidiasis in a patient with chronic lymphocytic leukemia and molecular characterization of the isolate. Kor J Parasitol 2008; 46:261-3.
http://dx.doi.org/10.3347/kjp.2008.46.4.261
 
19. Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005; 12:680-2.
PMid:15879034 PMCid:PMC1112072
 
20. Abdelrahman MZ, Zeehaida M, Rahmah N, et al. Fatal septicemic shock associated with Strongyloides stercoralis infection in a patient with angioimmunoblastic T-cell lymphoma: a case report and literature review. Parasitol Int 2012; 61:508-11.
http://dx.doi.org/10.1016/j.parint.2012.04.005
 
21. Rodrigues RM, de Oliveira MC, Sopelete MC, et al. IgG1, IgG4, and IgE antibody responses in human strongyloidiasis by ELISA using Strongyloides ratti saline extract as heterologous antigen. Parasitol Res 2007; 101:1209-14.
http://dx.doi.org/10.1007/s00436-007-0602-z
 
22. Lindo JF, Lee MG. Strongyloides stercoralis and S. fulleborni. In: Gillespie SH, Pearson RD, eds. Principles and Practice of Clinical Parasitology. 1st ed. New York: John Wiley & Sons, 2001: 479-92.
http://dx.doi.org/10.1002/0470842504.ch18c
 
23. Brooker S, Bundy DAP. Soil-transmitted helminths (geohelminths). In: Cook GC, Manson P, Zumla A, eds. Manson's Tropical Diseases. 22nd ed. Philadelphia: Saunders Limited, 2009: 1532-8.
 
24. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33:1040-7.
http://dx.doi.org/10.1086/322707
 
25. No authors listed. Parasitic infections. Am J Transplant 2004; 4(Suppl 10):142-55.
http://dx.doi.org/10.1111/j.1600-6135.2004.00677.x
 
26. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infec Dis 2009; 49:1411-23.
http://dx.doi.org/10.1086/630201

Inappropriate use of proton pump inhibitors in a local setting

Share this Article

Singapore Med J 2014; 55(7): 363-366; http://dx.doi.org/10.11622/smedj.2014087
Inappropriate use of proton pump inhibitors in a local setting

Chia C, Lim WP, Vu C
Correspondence: Dr Christopher Chia Tze Wei, christopher_tw_chia@ttsh.com.sg

ABSTRACT
INTRODUCTION There are growing concerns that the use of proton pump inhibitors (PPIs) may be inappropriate in instances that do not conform to evidence-based indications. This point-prevalence study aimed to investigate the frequency, indications and appropriateness of use of PPIs in hospitalised patients on a randomly chosen day.
METHODS On a randomly chosen day, all inpatients were documented, and those on any form of PPIs on that day were determined. Indications for maintaining these patients on PPIs were obtained from the electronic medical records, which were then recorded and cross-referenced against a list of accepted indications adapted from the US Food and Drug Administration (FDA)-approved list.
RESULTS In all, 1,025 inpatients were documented. Of the 477 (46.5%) inpatients using PPIs, only 219 (45.9%) fulfilled the FDA-approved indications, while the majority (n = 258, 54.1%) did not. Overall, PPIs were not strictly indicated for use in 206 (43.2%) inpatients, according to FDA criteria. Of the 477 inpatients on PPIs, 52 (10.9%) had borderline indications based on expert consensus/guidelines other than FDA criteria.
CONCLUSION Although the use of PPIs is prevalent in hospitals, less than half of the hospitalised patients using PPIs in our study had evidence-based indications that supported such use. The overuse of PPIs has a negative impact on healthcare costs and may lead to adverse effects. Steps to curb the inappropriate use of PPIs should address factors such as indications for the initiation of PPIs, and reassessment of the need for ongoing PPI use in inpatients upon discharge and during outpatient reviews.

Keywords: guidelines, hospitalised, inappropriate use, patients, proton pump inhibitors
Singapore Med J 2014; 55(7): 363-366; http://dx.doi.org/10.11622/smedj.2014087

REFERENCES

1. Regal RE, Osta AD, Parekh VI. Interventions to curb the overuse of Acid-suppressive medications on an inpatient general medicine service. P T 2010; 35:86-90.
 
2. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010; 16:e228-34.
PMid:21250399
 
3. Thomas L, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010; 16:122-9.
PMid:20178397
 
4. Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010; 49:2561-8.
http://dx.doi.org/10.2169/internalmedicine.49.4064
 
5. Bustamante Robles KY1, Ticse Aguirre R, Cánepa Rondo IF, et al. [Frequency of proton pump inhibitor prescription based in clinical practice guidelines in hospitalized patients in two academic hospitals in Lima, Peru]. Rev Gastroenterol Peru 2012; 32:44-9. Spanish.
PMid:22476177
 
6. FDA Center for Drug Evaluation and Research. New Drug Application (NDA) Nexium (esomeprazole magnesium) delayed release capsules. AstraZeneca LP. Application Number 21-153 & 21-154 [online]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021153Orig1s008.pdf. Accessed March 11, 2013.
 
7. National Institute for Clinical Excellence. Guidence of the use of proton pump inhibitors in the treatment of dyspepsia [online]. Available at: www.nice.org.uk/nicemedia/pdf/proton.pdf. Accessed March 11, 2013.
 
8. Lanza FF, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728-38.
http://dx.doi.org/10.1038/ajg.2009.115
 
9. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010; 5:288-97.
http://dx.doi.org/10.2174/157488410793352067
 
10. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95:3118-22.
http://dx.doi.org/10.1111/j.1572-0241.2000.02680.x
 
11. Salmasian H, Freedberg DE, Abrams JA, Friedman C. An automated tool for detecting medication overuse based on the electronic health records. Pharmacoepidemiol Drug Saf 2013; 22:183-9.
http://dx.doi.org/10.1002/pds.3387
 
12. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J 2010; 103:207-11.
http://dx.doi.org/10.1097/SMJ.0b013e3181ce0e7a
 
13. Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit 2008; 14:CR468-72.
PMid:18758417
 
14. Van Vliet EP, Otten HJ, Rudolphus A, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol 2008; 20:608-12.
http://dx.doi.org/10.1097/MEG.0b013e3282f52f95
 
15. Bez C, Perrottet N, Zingg T, et al. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract 2012; 19:378-8.
 
16. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22:205-10.
http://dx.doi.org/10.1016/j.ejim.2010.11.009
 
17. Glew CM, Rentler RJ. Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients. J Am Med Dir Assoc 2007; 8:607-9.
http://dx.doi.org/10.1016/j.jamda.2007.07.001
 
18. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007; 64:1396-400.
http://dx.doi.org/10.2146/ajhp060393
 
19. Scagliarini R, Magnani E, Praticò A, et al. Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci 2005; 50:2307-11.
http://dx.doi.org/10.1007/s10620-005-3052-4
 
20. Strid H, Simrén M, Björnsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrol Dial Transplant 2003; 18:570-5.
http://dx.doi.org/10.1093/ndt/18.3.570
 
21. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25:333-40.
http://dx.doi.org/10.1046/j.1365-2710.2000.00312.x
 
22. Omeprazole: Drug Information Lexicomp [online]. Available at: www.UpToDate.com. Accessed June 2011.
 
23. Eisai Inc. Aciphex prescribing information [online]. Available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=.... Accessed March 11, 2013.
 
24. AstraZeneca LP. Nexium prescribing information [online]. Available at: http://www1.astrazeneca-us.com/pi/Nexium.pdf. Accessed March 11, 2013.
 
25. TAP Pharmaceuticals Inc. Prevacid prescribing information [online]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020406s067,0212.... Accessed March 11, 2013.
 
26. AstraZeneca LP. Prilosec prescribing information [online]. Available at: http://www1.astrazeneca-us.com/pi/Prilosec.pdf. Accessed March 11, 2013.
 
27. Wyeth Pharmaceuticals Inc. Protonix prescribing information [online]. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=135. Accessed March 11, 2013.
 
28. Santarus Inc. Zegerid prescribing information [online]. Available at: http://www.zegerid.com/docs/zegerid-full-prescribing-information.pdf. Accessed March 11, 2013.

Characteristics of distractions in the intensive care unit: how serious are they and who are at risk?

Share this Article

Singapore Med J 2014; 55(7): 358-362; http://dx.doi.org/10.11622/smedj.2014086
Characteristics of distractions in the intensive care unit: how serious are they and who are at risk?

See KC, Phua J, Mukhopadhyay A, Lim TK
Correspondence: Dr Kay Choong See, Kay_Choong_SEE@nuhs.edu.sg

ABSTRACT
INTRODUCTION Distractions and interruptions of doctor’s work, although common and potentially deleterious in the intensive care unit (ICU), are not well studied.
METHODS We used a simple observational method to describe the frequency, sources and severity of such distractions, and explore at-risk situations in the ICU. Independent paired observers separately shadowed eight residents and three fellows for 38 sessions (over 100 hrs) in a 20-bed medical ICU.
RESULTS In total, 444 distractions were noted. Interobserver agreement was excellent at 99.1%. The mean number of distractions/doctor/hr was 4.36 ± 2.27. Median duration of each distraction was 2 mins (interquartile range 2–4 mins; range 1–20 mins). The top three initiators of distractions were other doctors (35.1%), nurses (30.4%) and oneself (18.7%). Of the 444 distractions, 107 (24.1%) were prolonged (lasting ≥ 5 mins), 210 (47.3%) led to a complete pause of current activity and 85 (19.1%) led to complete abandonment of the current activity. On multivariate analysis, physician seniority, time of session and day of week did not predict frequency of distraction. After adjusting for time of session, day of week and type of current activity, urgent distractions (to see another patient, perform immediate procedures or administer medications) and physician juniority were associated with major distractions (complete interruption or termination of current activity), while only urgent distractions were associated with prolonged distractions.
CONCLUSION Distractions are common in the ICU and junior doctors are particularly susceptible to major distractions.

Keywords: distraction, fellow, intensive care, interruption, resident
Singapore Med J 2014; 55(7): 358-362; http://dx.doi.org/10.11622/smedj.2014086

REFERENCES

1. Weigl M, Müller A, Zupanc A, Glaser J, Angerer P. Hospital doctors' workflow interruptions and activities: an observation study. BMJ Qual Saf 2011; 20:491-7.
http://dx.doi.org/10.1136/bmjqs.2010.043281
 
2. Westbrook JI, Woods A, Rob MI, Dunsmuir WT, Day RO. Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med 2010; 170:683-90.
http://dx.doi.org/10.1001/archinternmed.2010.65
 
3. Westbrook JI, Coiera E, Dunsmuir WT, et al. The impact of interruptions on clinical task completion. Qual Saf Health Care 2010; 19:284-9.
http://dx.doi.org/10.1136/qshc.2009.039255
 
4. Morris AH. Developing and implementing computerized protocols for standardization of clinical decisions. Ann Intern Med 2000; 132:373-83.
http://dx.doi.org/10.7326/0003-4819-132-5-200003070-00007
 
5. Ballermann MA, Shaw NT, Mayes DC, Gibney RT, Westbrook JI. Validationof the Work Observation Method By Activity Timing (WOMBAT) method of conducting time-motion observations in critical care settings: an observational study. BMC Med Inform Decis Mak 2011; 11:32.
http://dx.doi.org/10.1186/1472-6947-11-32
 
6. Brixey JJ, Tang Z, Robinson DJ, et al. Interruptions in a level one trauma center: a case study. Int J Med Inform 2008; 77:235-41.
http://dx.doi.org/10.1016/j.ijmedinf.2007.04.006
 
7. Brixey JJ, Robinson DJ, Turley JP, Zhang J. The roles of MDs and RNs as initiators and recipients of interruptions in workflow. Int J Med Inform 2010; 79:e109-15.
http://dx.doi.org/10.1016/j.ijmedinf.2008.08.007
 
8. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-7.
http://dx.doi.org/10.1016/S0140-6736(07)61602-X
 
9. Healey AN, Sevdalis N, Vincent CA. Measuring intra-operative interference from distraction and interruption observed in the operating theatre. Ergonomics 2006; 49:589-604.
http://dx.doi.org/10.1080/00140130600568899
 
10. Tang Z, Weavind L, Mazabob J, et al. Workflow in intensive care unit remote monitoring: A time-and-motion study. Crit Care Med 2007; 35:2057-63.
http://dx.doi.org/10.1097/01.CCM.0000281516.84767.96
 
11. Valentin A, Capuzzo M, Guidet B, et al. Patient safety in intensive care: results from the multinational Sentinel Events Evaluation (SEE) study. Intensive Care Med 2006; 32:1591-8.
http://dx.doi.org/10.1007/s00134-006-0290-7
 
12. Anthony K, Wiencek C, Bauer C, Daly B, Anthony MK. No interruptions please: impact of a No Interruption Zone on medication safety in intensive care units. Crit Care Nurse 2010; 30:21-9.
http://dx.doi.org/10.4037/ccn2010473
 
13. Relihan E, O'Brien V, O'Hara S, Silke B. The impact of a set of interventions to reduce interruptions and distractions to nurses during medication administration. Qual Saf Health Care 2010; 19:e52.
PMid:20511596
 
14. Cook RI, Render M, Woods DD. Gaps in the continuity of care and progress on patient safety. BMJ 2000; 320:791-4.
http://dx.doi.org/10.1136/bmj.320.7237.791
 
15. Montgomery VL. Effect of fatigue, workload, and environment on patient safety in the pediatric intensive care unit. Pediatr Crit Care Med 2007; 8:S11-6.
http://dx.doi.org/10.1097/01.PCC.0000257735.49562.8F
 
16. Magrabi F, Li SY, Day RO, Coiera E. Errors and electronic prescribing: a controlled laboratory study to examine task complexity and interruption effects. J Am Med Inform Assoc 2010; 17:575-83.
http://dx.doi.org/10.1136/jamia.2009.001719
 
17. Weinberg NS. The relation of medical problem solving and therapeutic errors to disease categories. QRB Qual Rev Bull 1989; 15:266-72.
PMid:2510109
 
18. Winters B, Custer J, Galvagno SM Jr, et al. Diagnostic errors in the intensive care unit: a systematic review of autopsy studies. BMJ Qual Saf 2012; 21:894-902.
http://dx.doi.org/10.1136/bmjqs-2012-000803

I-ROAD could be efficient in predicting severity of community-acquired pneumonia or healthcare-associated pneumonia

Share this Article

Singapore Med J 2014; 55(6): 318-324; http://dx.doi.org/10.11622/smedj.2014082
I-ROAD could be efficient in predicting severity of community-acquired pneumonia or healthcare-associated pneumonia

Matsunuma R, Asai N, Ohkuni Y, Nakashima K, Iwasaki T, Misawa M, Norihiro K
Correspondence: Dr Ryo Matsunuma, manutsuma@gmail.com

ABSTRACT
INTRODUCTION The ability to predict the prognosis of patients with pneumonia is critical, especially when making decisions regarding treatment regimens and sites of care. However, prognostic guidelines for healthcare-associated pneumonia (HCAP) have yet to be established. I-ROAD is the prognostic guideline of the Japanese Respiratory Society for hospital-acquired pneumonia (HAP). This study compared available prognostic guidelines to determine the usefulness of I-ROAD as a prognostic tool for patients with HCAP.
METHODS We conducted a retrospective review of all patients with pneumonia admitted to Kameda Medical Center, Japan, from January 2006 to September 2009. Patients were categorised into two groups, namely those with communityacquired pneumonia (CAP) and those with HCAP. We compared the baseline characteristics, laboratory findings, identified pathogens, antibiotic regimens, clinical outcomes, pneumonic severity and prognostic accuracy of each guideline between the two patient groups. The severity of each disease was assessed on admission using the A-DROP, CURB-65, PSI and I-ROAD guidelines.
RESULTS Of the 302 patients evaluated, 228 (75.5%) were diagnosed with CAP and 74 (24.5%) with HCAP. Patients with HCAP were older and had a higher performance status than patients with CAP. The mortality rate in the CAP group tended to rise with increasing severity scores of prognostic guidelines. Although the severity scores of all prognostic guidelines could predict 30-day mortality in patients with CAP, I-ROAD exhibited a higher discriminatory power for patients with HCAP based on analysis of receiver-operating characteristic curves.
CONCLUSION I-ROAD could be more accurate than other prognostic guidelines for evaluating the severity of HCAP.

Keywords: community-acquired pneumonia, healthcare-associated pneumonia, I-ROAD, prognostic tools, severity
Singapore Med J 2014; 55(6): 318-324; http://dx.doi.org/10.11622/smedj.2014082

REFERENCES

1. Miyashita N, Matsushima T, Oka M; Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 2006; 45:419-28.
http://dx.doi.org/10.2169/internalmedicine.45.1691
 
2. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56(Suppl 4):1-64.
http://dx.doi.org/10.1136/thx.56.suppl_4.iv1
 
3. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
http://dx.doi.org/10.1164/ajrccm.163.7.at1010
 
4. American Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
http://dx.doi.org/10.1164/rccm.200405-644ST
 
5. Japanese Respiratory Society. Establishment of new severity ratings based on analysis of hospital-acquired pneumonia. Respirology 2009; 14 (Suppl 2) S4-S9.
http://dx.doi.org/10.1111/j.1440-1843.2009.01571.x
 
6. Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology 2008; 13: 880-5.
http://dx.doi.org/10.1111/j.1440-1843.2008.01348.x
 
7. Zubrod CG, Sheiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960; 11:7-33.
http://dx.doi.org/10.1016/0021-9681(60)90137-5
 
8. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. Vol 28. M100 S18. Wayne, Pennsylvania: CLSI, 2008.
 
9. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-9.
http://dx.doi.org/10.1164/ajrccm.157.2.9705064
 
10. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-51.
http://dx.doi.org/10.1128/CMR.14.4.933-951.2001
 
11. Aujesky D, Auble TE, Yearly DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005: 118;384-92.
http://dx.doi.org/10.1016/j.amjmed.2005.01.006
 
12. Usui K, Tanaka Y, Noda H, Ishihara T. [Comparison of three prediction rules for prognosis in community acquired pneumonia : Pneumonia Severity Index (PSI), CURB-65, and A-DROP]. Nihon Kokyuki Gakkai Zasshi 2009; 47:781-5. Japanese.
 
13. Higuchi T, Ota K, Tanabe Y, Suzuki E, Gejyo F. [Severity classification and prognosis in hospitalized elderly patients with community-acquired pneumonia]. Nihon Ronen Igakkai Zasshi 2007; 44:483-9. Japanese.
http://dx.doi.org/10.3143/geriatrics.44.483
 
14. Liapikou A, Ferrer M, Polverino E, et al. Severe community community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48: 377-85.
http://dx.doi.org/10.1086/596307
 
15. Carrabba M, Zarantonello M, Bonara P, et al. Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression. Eur Respir J 2012; 40:1201-10.
http://dx.doi.org/10.1183/09031936.00187811
 
16. Jeong BH, Koh WJ, Yoo H, et al. Performances of prognostic scoring systems in patients with healthcare-associated pneumonia. Clin Infect Dis 2013;56:625-32.
http://dx.doi.org/10.1093/cid/cis970
 
17. Ministry of Health, Labour and Welfare, Insurance Department. Patients report. Tokyo, 2011. Available at: http://www.mhlw.go.jp/toukei/saikin/hw/kanja/11/dl/toukei.pdf. Accessed March 10, 2013.
 
18. Shindo Y, Sato S, Maruyama E, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009; 135:633-40.
http://dx.doi.org/10.1378/chest.08-1357
 
19. Grenier C, Pépin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011; 66:1617-24.
http://dx.doi.org/10.1093/jac/dkr176
 
20. Sugisaki M, Enomoto T, Shibuya Y, et al. Clinical characteristics of healthcare-associated pneumonia in a public hospital in a metropolitan area of Japan. J Infect Chemother 2012; 18:352-60.
http://dx.doi.org/10.1007/s10156-011-0344-9
 
21. Jung JY, Park MS, Kim YS, et al. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis 2011; 11:61.
http://dx.doi.org/10.1186/1471-2334-11-61
 
22. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010; 10:279-87.
http://dx.doi.org/10.1016/S1473-3099(10)70032-3

Reappraisal of twinning: epidemiology and outcome in the early neonatal period

Share this Article

Singapore Med J 2014; 55(6): 310-317; http://dx.doi.org/10.11622/smedj.2014083
Reappraisal of twinning: epidemiology and outcome in the early neonatal period

Gupta P, Faridi MM, Goel N, Zaidi ZH
Correspondence: Dr Priyanka Gupta, drpriyankaguptakapil@gmail.com

ABSTRACT
INTRODUCTION
The present study aimed to determine the epidemiology, maternal complications and adverse neonatal outcomes associated with twin births at a tertiary care hospital in India.
METHODS A prospective observational study was conducted on all successively born twin pairs (≥ 23 weeks of gestation) and their mothers from January to September 2005. Main outcome measures included maternal medical/obstetric complications, labour characteristics and the morbidities/mortality observed during the early neonatal period.
RESULTS The twinning rate was 1 in 54 deliveries. Around 10% of mothers had a predisposition for twinning in the form of familial tendency or consumption of clomiphene. Anaemia (85%) was the most common maternal complication, followed by gestational hypertension (17%). Nearly one-third of births were delivered via Caesarean section. Prematurity (61%) was the most common neonatal complication followed by early-onset neonatal sepsis (21%). The risk of early neonatal death was 27%. Shorter gestation and low birth weight were significantly associated with adverse neonatal outcome (p < 0.05). Factors such as chorionicity, mode of delivery, birth order, inter-twin delivery time interval, gender and intra-pair birth weight discordance did not affect neonatal morbidity or mortality (p ≥ 0.05).
CONCLUSION The rates of maternal complications and early neonatal morbidities/mortality were quite high in twin gestations. Except for the prematurity and low birth weight, none of the other factors, including inter-twin delivery time interval of more than 15 mins, were found to affect neonatal outcome.

Keywords: inter-twin delivery time interval, morbidities, mortality, twins
Singapore Med J 2014; 55(6): 310-317; http://dx.doi.org/10.11622/smedj.2014083

REFERENCES

1. Cunningham FG, Leveno KJ, Bloom SL, et al. Multifetal gestation. In: Cunningham FG, Leveno KJ, Bloom SL, et al, eds. Williams Obstetrics, 22nd ed. New York: McGraw-Hill, 2005: 911-948.
 
2. MacGillivray I. Epidemiology of twin pregnancy. Semin Perinatol 1986; 10: 4-8.
 
3. Isiaka-lawal S, Adesina KT, Saidu R, et al. A review of twin gestation in a tertiary health institution in North Central Nigeria. Res J Med Sci 2009; 3:198-201.
 
4. Satija M, Sharma S, Soni RK, Sachar RK, Singh GP. Twinning and its correlates: community-based study in a rural area of India. Hum Biol 2008; 80:611-21.
http://dx.doi.org/10.3378/1534-6617-80.6.611
 
5. Mutihir JT, Pam VC. Obstetric outcome of twin pregnancies in Jos, Nigeria. Niger J Clin Pract 2007; 10:15-8.
 
6. Ghai V, Vidyasagar D. Morbidity and mortality factors in twins. An epidemiologic approach. Clin Perinatol 1988; 15:123-40.
 
7. Ho SK, Wu PY. Perinatal factors and neonatal morbidity in twin pregnancy. Am J Obstet Gynecol 1975; 122: 979-87. 11 Machin GA. Why is it important to diagnose chorionicity and how do we do it? Best Pract Res Clin Obstet Gynaecol 2004; 18:515-30.
 
8. Suri K, Bhandari V, Lerer T, Rosenkrantz TS, Hussain N. Morbidity and mortality of preterm twins and higher-order multiple births. J Perinatol 2001; 21:293-9.
http://dx.doi.org/10.1038/sj.jp.7200492
 
9. Eskes TK, Timmer H, Kollée LA, Jongsma HW. The second twin. Eur J Obstet Gynecol Reprod Biol 1985; 19:159-66.
http://dx.doi.org/10.1016/0028-2243(85)90150-9
 
10. Breeze A, Smith G. Mode of delivery of twins. Risk Management – The Obstetrician and Gynaecologist 2004; 6:222-6.
http://dx.doi.org/10.1576/toag.6.4.222.27019
 
12. Chen SJ, Vohr BR, Oh W. Effects of birth order, gender, and intrauterine growth retardation on the outcome of very low birth weight in twins. J Pediatr 1993; 123:132-6.
http://dx.doi.org/10.1016/S0022-3476(05)81556-2
 
13. Fraser D, Picard R, Picard E, Leiberman JR. Birth weight discordance, intrauterine growth retardation and perinatal outcomes in twins. J Reprod Med 1994; 39: 504-8.
 
14. Shinwell ES, Blickstein I, Lusky A, Reichman B. Effect of birth order on neonatal morbidity and mortality among very low birthweight twins: a population based study. Arch Dis Child Fetal Neonatal Ed 2004; 89: F145-8.
http://dx.doi.org/10.1136/adc.2002.021584
 
15. Smith GC, Fleming KM, White IR. Birth order of twins and risk of perinatal death related to delivery in England, Northern Ireland, and Wales, 1994-2003: retrospective cohort study. BMJ 2007; 334: 576.
http://dx.doi.org/10.1136/bmj.39118.483819.55
 
16. Haest KM, Roumen FJ, Nijhuis JG. Neonatal and maternal outcomes in twin gestations > or =32 weeks according to the planned mode of delivery. Eur J Obstet Gynecol Reprod Biol 2005; 123:17-21.
http://dx.doi.org/10.1016/j.ejogrb.2005.02.007
 
17. Cetrulo CL. The controversy of mode of delivery in twins: the intrapartum management of twin gestation (Part 1). Semin Perinatol 1986; 10:39-43.
 
18. Erdemoglu E, Mungan T, Tapisiz OL, Ustunyurt E, Caglar E. Effect of inter-twin delivery time on Apgar scores of the second twin. Aust N Z J Obstet Gynaecol 2003; 43:203-6.
http://dx.doi.org/10.1046/j.0004-8666.2003.00056.x
 
19. Suh YH, Park KH, Hong JS, et al. Relationship between twin-to-twin delivery interval and umbilical artery acid-base status in the second twin. J Korean Med Sci 2007; 22:248-53.
http://dx.doi.org/10.3346/jkms.2007.22.2.248
 
20. Hartley RS, Hitti J. Birth order and delivery interval: analysis of twin pair perinatal outcomes. J Matern Fetal Neonatal Med 2005; 17:375-80.
http://dx.doi.org/10.1080/147670505000132484
 
21. Armson BA, O'Connell C, Persad V, et al. Determinants of perinatal mortality and serious neonatal morbidity in the second twin. Obstet Gynecol 2006; 108:556-64.
http://dx.doi.org/10.1097/01.AOG.0000227747.37184.0a
 
22. Farooqui MO, Grossman JH 3rd, Shannon RA. A review of twin pregnancy and perinatal mortality. Obstet Gynecol Surv 1973; 28 Suppl:144-53.
http://dx.doi.org/10.1097/00006254-197302000-00026
 
23. Rydhström H, Ingemarsson I. Interval between birth of the first and the second twin and its impact on second twin perinatal mortality. J Perinat Med 1990; 18:449-53.
http://dx.doi.org/10.1515/jpme.1990.18.6.449
 
24. McGrail CD, Bryant DR. Intertwin time interval: how it affects the immediate neonatal outcome of the second twin. Am J Obstet Gynecol 2005; 192:1420-2.
http://dx.doi.org/10.1016/j.ajog.2005.02.079
 
25. Nassar AH, Usta IM, Khalil AM, Aswad NA, Seoud MA. Neonatal outcome of growth discordant twin gestations. J Perinat Med 2003; 31:330-6.
http://dx.doi.org/10.1515/JPM.2003.047
 
26. Hollier LM, McIntire DD, Leveno KJ. Outcome of twin pregnancies according to intrapair birth weight differences. Obstet Gynecol 1999; 94:1006-10.
http://dx.doi.org/10.1016/S0029-7844(99)00500-1
 
27. Collins JW, David RJ, Boehm JJ. Respiratory distress syndrome explains sex but not race differences in birth weight specific mortality. Pediatr Res 1987; 21:393-7.
 
28. Tan KL. Neonatal jaundice in twins. Aust Paediatr J 1980; 16:70-2.
 
29. Cohen SB, Elizur SE, Goldenberg M, et al. Outcome of twin pregnancies with extreme weight discordancy. Am J Perinatol 2001; 18:427-32.
http://dx.doi.org/10.1055/s-2001-18789
 
30. Tan H, Wen SW, Fung Kee Fung K, Walker M, Demissie K. The distribution of intra-twin birth weight discordance and its association with total twin birth weight, gestational age, and neonatal mortality. Eur J Obstet Gynecol Reprod Biol 2005; 121:27-33.
http://dx.doi.org/10.1016/j.ejogrb.2004.10.012
 
31. Wiswell TE, Hankins CT. Twins and triplets with necrotizing enterocolitis. Am J Dis Child 1988; 142:1004-6.
 
32. Samm M, Curtis-Cohen M, Keller M, Chawla H. Necrotizing enterocolitis in infants of multiple gestation. Am J Dis Child 1986; 140:937-9.
 
33. Ballard JL, Khoury JC, Wedig K, et al. New Ballard Score expanded to include extremely premature infants. J Pediatr 1991; 119:417-23.
http://dx.doi.org/10.1016/S0022-3476(05)82056-6
 
34. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatrics 2003; 3:13.
http://dx.doi.org/10.1186/1471-2431-3-13
 
35. Gupta P, Faridi MM, Shah D, Dev G. BCG reaction in twin newborns: Effect of zygosity and chorionicity. Indian Pediatr 2008; 45:271-7.
 
36. Chia KS, Lee JJ, Cheung P, et al. Twin births in Singapore: a population-based study using the National Birth Registry. Ann Acad Med Singapore 2004; 33:195-9.
 
37. Smits J, Monden C. Twinning across the developing world. PLoS One 2011; 6: e25239.
http://dx.doi.org/10.1371/journal.pone.0025239
 
38. Musili F, Karanja JG. Multifoetal pregnancies at a maternity hospital in Nairobi. East Afr Med J 2009; 86: 162-5.
http://dx.doi.org/10.4314/eamj.v86i4.46945
 
39. Lam H, Ho PC. Comparison of pregnancy outcome between high- order multiple and twin pregnancies: matched-pair retrospective study. Hong Kong Med J 1999; 5:16-20.
 
40. Benirschke K, Masliah E. The placenta in multiple pregnancy: outstanding issues. Reprod Fertil Dev 2001; 13: 615-22.
http://dx.doi.org/10.1071/RD01037
 
41. Newman RB. Multiple gestation. In: Scott JR, Gibbs RS, Karlan BY, Haney AF, Danforth DN, eds. Danforth's Obstetrics and Gynecology. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2003: 225-45.
 
42. Tan KH, Kwek K, Yeo GS. Epidemiology of pre-eclampsia and eclampsia at the KK Women's and Children's Hospital, Singapore. Singapore Med J 2006; 47:48-53.
 
43. National Family Health Survey (NFHS)-3. IIPS, Mumbai 2005-2006. Ministry of Health & Family Welfare, Govt. of India.
 
44. Gupta P, Murali MV, Faridi MM, et al. Clinical profile of klebsiella septicemia in neonates. Indian J Pediatr 1993; 60:565-72.
http://dx.doi.org/10.1007/BF02751435

Female ageing and reproductive outcome in assisted reproduction cycles

Share this Article

Singapore Med J 2014; 55(6): 305-309; http://dx.doi.org/10.11622/smedj.2014081
Female ageing and reproductive outcome in assisted reproduction cycles

Tan TY, Lau SK, Loh SF, Tan HH
Correspondence: Dr Matthew Lau Sie Kuei, matthew.lau.sk@kkh.com.sg

ABSTRACT
INTRODUCTION Fertility in women declines with increasing age. With the deferment of marriage and childbearing, couples are turning to assisted reproductive technology to counteract this decline. We aimed to evaluate the results of in vitrofertilisation (IVF)/intracytoplasmic sperm injection (ICSI) in women of different age groups, and highlight the cost-effectiveness of IVF treatment in these groups while assessing its implications on the national healthcare provision model.
METHODS Retrospective analysis of 3,412 stimulated IVF/ICSI cycles in a hospital-based IVF centre was performed from January 2008 to December 2010. Patients were stratified into seven age groups: < 30 years; 30–35 years; 36–37 years; 38 years; 39 years; 40–44 years; and ≥ 45 years.
RESULTS Age had a significant effect on the number of cycles leading to embryo transfer (p < 0.001). The number of oocytes retrieved decreased across the various age groups (p < 0.001) and was the highest among women aged < 30 (mean 18.5 ± 10.3) years. With increasing age, there was a trend toward a lower fertilisation rate. Age also had a significant effect on the rates of clinical pregnancy, live birth and multiple pregnancies (p < 0.001).
CONCLUSION Patients aged < 30 years had the best IVF outcomes, refl ecting optimal reproductive capacity. Age-related decline in fertility starts after 30 years. Women opting for IVF should be counselled about age-specific success rates while taking into account individual risk factors.

Keywords: clinical pregnancy rate, female ageing, in vitrofertilisation outcome, live birth rate, miscarriage rate
Singapore Med J 2014; 55(6): 305-309; http://dx.doi.org/10.11622/smedj.2014081

REFERENCES

1. Speroff L. The effect of aging on fertility. Curr Opin Obstet Gynecol 1994; 6:115-20.
http://dx.doi.org/10.1097/00001703-199404000-00002
 
2. Dicker D, Goldman JA, Ashkenazi J, et al. Age and pregnancy rates in in-vitro fertilization. J In Vitro Fert Embryo Transf 1991; 8:141-4.
http://dx.doi.org/10.1007/BF01131703
 
3. Scwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med 1982; 306:404-6.
http://dx.doi.org/10.1056/NEJM198202183060706
 
4. Human Fertilization and Embryo Authority. The patients' guide to DI and IVF clinic. London: Human Fertilization and Embryo Authority, 1996.
 
5. Rutherford AJ, Subak-Sharpe RJ, Dawson KJ, et al. Improvement of in-vitro fertilization after treatment with buserelin, an agonist of luteinising hormone releasing hormone. Br Med J (Clin Res Ed) 1988; 296:1765-8.
http://dx.doi.org/10.1136/bmj.296.6639.1765
 
6. Lass A, Croucher C, Duffy S, et al. One thousand initiated cycles of in-vitro fertilization in women > or = 40 years of age. Fertil Steril 1998; 70:1030-4.
http://dx.doi.org/10.1016/S0015-0282(98)00353-7
 
7. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992; 7:1342-6.
 
8. Menken J, Trussell J, Larsen U. Age and infertility. Science 1986; 233:1389-94.
http://dx.doi.org/10.1126/science.3755843
 
9. Simpson JL. Lobo RA, Kelsey J, Marcus R, eds. Genetic programming in ovarian development and oogenesis. Menopause: biology and pathobiology. San Diego: Academic Press, 2000: 77-94.
 
10. Navot D, Bergh PA, Williams MA, et al. Poor oocytes quality rather than implantation failure as a cause of age-related decline in female fertility. Lancet 1991; 337:1375-7.
http://dx.doi.org/10.1016/0140-6736(91)93060-M
 
11. Hull MGR, Fleming CF, Hughes AO, McDermott A. The age-related decline in female fecundity: A quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization. Fertil Steril 1996; 65:783-90.
 
12. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976; 42:629-36.
http://dx.doi.org/10.1210/jcem-42-4-629
 
13. Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilization treatment. Lancet 1996; 348:1402-6.
http://dx.doi.org/10.1016/S0140-6736(96)05291-9
 
14. Department of Statistics Singapore. Age Specific Marriage Rates. Copyright Government of Singapore.
 
15. Department of Statistics Singapore. Age Specific Fertility Rates. Copyright Government of Singapore.
 
16. Loh FH, Khin LW, Saw SM, Lee JJ, Gu K.The age of menopause and the menopause transition in a multiracial population: a nation-wide Singapore study. Maturitas 2005; 52:169-80.
http://dx.doi.org/10.1016/j.maturitas.2004.11.004
 
17. Ron-El R, Raziel A, Strassburger D, et al. Outcome of assisted reproductive technology in women over the age of 41. Fertil Steril 2000; 74:471-5.
http://dx.doi.org/10.1016/S0015-0282(00)00697-X
 
18. Viardot-Foucault V, Tai BC, Oo SY, et al. Cumulative success rates after IVF treatment: longitudinal study from a single centre. Reproductive Endocrinology and ART: A celebratory congress. Canada, 2011.
 
19. Warbuton D, Kline J, Stein Z, et al. Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion? Evidence from 273 women with two karyotyped spontaneous abortions. Am J Hum Genet 1987; 41:465-83.
 
20. Suchartwatnachai C, Wongkularb A, Srisombut C, et al. Cost effectiveness of IVF in women 38 years and older. Int J Gynaecol Obstet 2000; 69:143-8.
http://dx.doi.org/10.1016/S0020-7292(99)00215-5
 
21. Griffiths A, Dyer SM, Lord SJ, et al. A Cost effectiveness analysis of in-vitro fertilization by maternal age and number of treatment attempts. Hum Reprod 2010; 25:924-31.
http://dx.doi.org/10.1093/humrep/dep418

Coarctation of the aorta: nonsurgical treatment using stent implantation

Share this Article

Singapore Med J 2014; 55(6): 302-304; http://dx.doi.org/10.11622/smedj.2014080
Coarctation of the aorta: nonsurgical treatment using stent implantation

Ang HL, Lim CW, Hia C, Yip J, Quek SC
Correspondence: Dr Quek Swee Chye, swee _chye _quek@nuhs.edu.sg

ABSTRACT
INTRODUCTION Coarctation of the aorta (CoA) accounts for 5%–8% of all congenital heart defects. If left untreated, most patients with significant CoA will have varying degrees of morbidity (e.g. hypertension, stroke, collateral formation and ventricular hypertrophy), possibly even mortality. Traditionally, treatment for this condition is surgical. Herein, we report stenting during catheterisation as an alternative nonsurgical treatment option for patients with CoA, and present the treatment outcomes of patients who underwent this treatment option.
METHODS We retrospectively reviewed four patients (2 men and 2 women; age range 20–41 years) who underwent CoA stenting under general anaesthesia for the treatment of native CoA or restenosis of CoA at our institution. Three patients had a 40-mm Palmaz stent inserted, while one had a 39-mm Cheatham-Platinum covered stent inserted. Angiography and measurement of pressure gradients were performed before and after stent implantation to ensure good treatment outcomes.
RESULTS The patients’ treatment outcomes were good, with a significant reduction in pressure gradients across the narrowed segments. Angiography showed relief of CoA. The patients were followed up for 1–3 years, during which no complications were noted.
CONCLUSION This is the first reported series in Singapore on the nonsurgical treatment of CoAs in adult patients using stents during interventional cardiac catheterisation. This less invasive procedure may lead to a new paradigm shift with regard to the treatment of CoA.

Keywords: angiogram, aortic coarctation, cardiac catheterisation, pressure gradients, stent
Singapore Med J 2014; 55(6): 302-304; http://dx.doi.org/10.11622/smedj.2014080

REFERENCES

1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39: 1890-900.
http://dx.doi.org/10.1016/S0735-1097(02)01886-7
 
2. Campbell M. Natural history of coarctation of the aorta. Br Heart J 1970; 32:633-40.3.
 
3. Crafoord C, Nylin G. Congenital coarctation of the aorta and its surgical treatment. J Thorac Surg 1945; 14:347-61.
 
4. Harrison DA, McLaughlin PR, Lazzam C, Connelly M, Benson LN. Endovascular stents in the management of coarctation of the aorta in the adolescent and adult: one year follow up. Heart 2001; 85:561-6.
http://dx.doi.org/10.1136/heart.85.5.561
 
5. Hamdan MA, Maheshwari S, Fahey JT, Hellenbrand WE. Endovascular stents for coarctation of the aorta: initial results and intermediate-term follow-up. J Am Coll Cardiol 2001; 38:1518-23.
http://dx.doi.org/10.1016/S0735-1097(01)01572-8
 
6. De Lezo JS, Sancho M, Pan M, et al. Angiographic follow-up after balloon angioplasty for coarctation of the aorta. J Am Coll Cardiol 1989; 13:689-95.
http://dx.doi.org/10.1016/0735-1097(89)90612-8
 
7. Rico J, Sobrino N, Calvo L, et al. [Percutaneous transluminal angioplasty in aortic coarctation in young adults]. Rev Esp Cardiol 1989; 42: 415-7. Spanish.
 
8. Kulick DL, Kotlewski A, Hurvitz RJ, Jamison M, Rahimtoola SH. Aortic rupture following percutaneous catheter balloon coarctoplasty in an adult. Am Heart J 1990; 119:190-3.
http://dx.doi.org/10.1016/S0002-8703(05)80101-2
 
9. Fawzy ME, Sivanandam V, Galal O, et al. One- to ten-year follow-up results of balloon angioplasty of native coarctation of the aorta in adolescents and adults. J Am Coll Cardiol 1997; 30:1542-6.
http://dx.doi.org/10.1016/S0735-1097(97)00350-1
 
10. Phadke K, Dyet JF, Aber CP, Hartley W. Balloon angioplasty of adult aortic coarctation. Br Heart J 1993; 69:36-40.
http://dx.doi.org/10.1136/hrt.69.1.36
 
11. Fletcher SE, Nihill MR, Grifka RG, O'Laughlin MP, Mullins CE. Balloon angioplasty of native coarctation of the aorta: midterm follow-up and prognostic factors. J Am Coll Cardiol 1995; 25:730-4.
http://dx.doi.org/10.1016/0735-1097(94)00437-U
 
12. Schräder R, Bussmann WD, Jacobi V, Kadel C. Long-term effects of balloon coarctation angioplasty on arterial blood pressure in adolescent and adult patients. Cathet Cardiovasc Diagn 1995; 36:220-5.
http://dx.doi.org/10.1002/ccd.1810360306
 
13. Biswas PK, Mitra K, De S, et al. Follow-up results of balloon angioplasty for native coarctation of aorta. Indian Heart J 1996; 48:673-6.
 
14. Eicken A, Pensl U, Sebening W, et al. The fate of systemic blood pressure in patients after effectively stented coarctation. Eur Heart J 2006; 27:1100-5.
http://dx.doi.org/10.1093/eurheartj/ehi748
 
15. Musto C, Cifarelli A, Pucci E, et al. Endovascular treatment of aortic coarctation: long-term ef fects on hypertension. Int J Cardiol 2008; 130:420-5.
http://dx.doi.org/10.1016/j.ijcard.2007.08.130
 
16. Macdonald S, Thomas SM, Cleveland TJ, Gaines PA. Angioplasty or stenting in adult coarctation of the aorta? A retrospective single center analysis over a decade. Cardiovasc Intervent Radiol 2003; 26:357-64.
http://dx.doi.org/10.1007/s00270-003-2709-7
 
17. Forbes TJ, Garekar S, Amin Z, et al. Procedural results and acute complications in stenting native and recurrent coarctation of the aorta in patients over 4 years of age: a multi-institutional study. Catheter Cardiovasc Interv 2007; 70:276-85.
http://dx.doi.org/10.1002/ccd.21164
 
18. Golden AB, Hellenbrand WE. Coarctation of the aorta: stenting in children and adults. Catheter Cardiovasc Interv 2007; 69:289-99.
http://dx.doi.org/10.1002/ccd.21009
 
19. Moltzer E, Roos-Hesselink JW, Yap SC, et al. Endovascular stenting for aortic (re)coarctation in adults. Neth Heart J 2010; 18:430-6.
http://dx.doi.org/10.1007/BF03091810
 
20. 20. Mahadevan VS, Vondermuhll IF, Mullen MJ. Endovascular aortic coarctation stenting in adolescents and adults: angiographic and hemodynamic outcomes. Catheter Cardiovasc Interv 2006; 67:268-75.
http://dx.doi.org/10.1002/ccd.20585
 
21. Tanous D, Collins N, Dehghani P, Horlick EM, Benson LN. Covered stents in the management of coarctation of the aorta in the adult: initial results and 1-year angiographic and hemodynamic follow-up. Int J Cardiol 2010; 140:287-95.
http://dx.doi.org/10.1016/j.ijcard.2008.11.085
 
22. Chessa M, Carrozza M, Butera G, et al. Results and mid-long-term follow-up of stent implantation for native and recurrent coarctation of the aorta. Eur Heart J 2005; 26:2728-32.
http://dx.doi.org/10.1093/eurheartj/ehi491
 
23. Egan M, Holzer RJ. Comparing balloon angioplasty, stenting and surgery in the treatment of aortic coarctation. Expert Rev Cardiovasc Ther 2009; 7:1401-12.
http://dx.doi.org/10.1586/erc.09.111
 
24. Qureshi AM, McElhinney DB, Lock JE, et al. Acute and intermediate outcomes, and evaluation of injury to the aortic wall, as based on 15 years' experience of implanting stents to treat aortic coarctation. Cardiol Young 2007; 17:307-18.
http://dx.doi.org/10.1017/S1047951107000339
 
25. Chen SS, Donald AE, Storry C, et al. Impact of aor tic stenting on peripheral vascular function and daytime systolic blood pressure in adult coarctation. Heart 2008; 94:919-24.
http://dx.doi.org/10.1136/hrt.2006.109389
 
26. Karl TR. Surgery is the best treatment for primary coarctation in the majority of cases. J Cardiovasc Med (Hagerstown) 2007; 8:50-6.
http://dx.doi.org/10.2459/01.JCM.0000247436.05194.c7

Vitamin D deficiency remains prevalent despite increased laboratory testing in New South Wales, Australia

Share this Article

Singapore Med J 2014; 55(5): 271-280; http://dx.doi.org/10.11622/smedj.2014071
Vitamin D deficiency remains prevalent despite increased laboratory testing in New South Wales, Australia

Quaggiotto P, Tran H, Bhanugopan M
Correspondence: Dr Paul Quaggiotto, apollo13@netspace.net.au

ABSTRACT
INTRODUCTION The aim of the present study was to assess the prevalence of vitamin D deficiency and toxicity, the frequency of 25-hydroxyvitamin D (25[OH]D) testing, and 25(OH)D variations with respect to patient gender, patient age and season in New South Wales, Australia.
METHODS A retrospective analysis of pathology records was performed to ascertain patient age, patient gender, sample collection date, plasma or serum 25(OH)D levels, calcium and parathyroid hormone (PTH) levels, and test numbers between 2001 and 2010. Linear regression with Bonferroni correction was used to calculate and compare age-adjusted mean 25(OH)D levels. Relationships of 25(OH)D with PTH and calcium were tested using Spearman’s rank correlation.
RESULTS 25(OH)D testing increased by 730% over the ten-year study period. In 2010, many men (33%) and women (40%) were, to some degree, vitamin D deficient (≤ 50 nmol/L). Vitamin D toxicity was rare, with only one instance noted. 25(OH)D levels correlated positively with calcium and negatively with PTH levels. 25(OH)D levels decreased with age. In 2010, 25(OH)D levels were highest in February and lowest in September/October. Cyclical variation was observed for 25(OH)D levels between 2006 and 2010.
CONCLUSION We found that vitamin D deficiency was prevalent in both men and women, with a higher prevalence in the latter, despite the substantial increased demand for 25(OH)D testing in our population over the decade. Vitamin D deficiency was associated with elevated PTH levels. Vitamin D toxicity was rare and only observed once during our study period. 25(OH)D levels decreased with age and varied with season, with the highest levels observed in late summer and the lowest in early spring.

Keywords: 25-hydroxyvitamin D, age, calcium, deficiency, toxicity
Singapore Med J 2014; 55(5): 271-280; http://dx.doi.org/10.11622/smedj.2014071

REFERENCES

1. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81:353-73.
http://dx.doi.org/10.4065/81.3.353
 
2. Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K. Vitamin D - a review. Aust Fam Physician 2008; 37:1002-5.
PMid:19142273
 
3. Chen TC, Chimeh F, Lu Z, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007; 460:213-7.
http://dx.doi.org/10.1016/j.abb.2006.12.017
 
4. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002; 22:139-66.
http://dx.doi.org/10.1146/annurev.nutr.22.120501.150216
 
5. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29:664-73.
http://dx.doi.org/10.1016/j.tibs.2004.10.005
 
6. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81.
http://dx.doi.org/10.1056/NEJMra070553
 
7. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008; 87: 1087S-91S.
PMid:18400739
 
8. Shroff R, Knott C, Rees L. The virtues of vitamin D - but how much is too much? Pediatr Nephrol 2010; 25:1607-20.
http://dx.doi.org/10.1007/s00467-010-1499-9
 
9. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-30.
http://dx.doi.org/10.1210/jc.2011-0385
 
10. Working Group of the Australian and New Zealand Bone and Mineral Society. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005; 182:281-5.
PMid:15777143
 
11. Hekimsoy Z, Dinç G, Kafesçiler S, et al. Vitamin D status among adults in the Aegean region of Turkey. BMC Public Health 2010; 10:782.
http://dx.doi.org/10.1186/1471-2458-10-782
 
12. Kuchuk NO, Pluijm SM, van Schoor NM, et al. Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab 2009; 94:1244-50.
http://dx.doi.org/10.1210/jc.2008-1832
 
13. Billoo AG, Murtaza G, Memon MA, et al. Comparison of oral versus injectable vitamin-D for the treatment of nutritional vitamin D deficiency rickets. J Coll Physicians Surg Pak 2009; 19:428-31.
PMid:19576150
 
14. Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab 2011; 25:585-91.
http://dx.doi.org/10.1016/j.beem.2011.05.002
 
15. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009; 205:255-60.
http://dx.doi.org/10.1016/j.atherosclerosis.2008.10.033
 
16. Williams S, Malatesta K, Norris K. Vitamin D and chronic kidney disease. Ethn Dis 2009; 19: S5-8-11.
 
17. Penckofer S, Kouba J, Wallis DE, Emanuele MA. Vitamin D and diabetes: let the sunshine in. Diabetes Educ 2008; 34:939-40.
http://dx.doi.org/10.1177/0145721708326764
 
18. Raghuwanshi A, Joshi SS, Christakos S. Vitamin D and multiple sclerosis. J Cell Biochem 2008; 105:338-43.
http://dx.doi.org/10.1002/jcb.21858
 
19. Lane NE. Vitamin D and systemic lupus erythematosus: bones, muscles, and joints. Curr Rheumatol Rep 2010; 12:259-63.
http://dx.doi.org/10.1007/s11926-010-0106-1
 
20. Rovner AJ, Stallings VA, Schall JI, Leonard MB, Zemel BS. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr 2007; 86:1694-9.
PMid:18065588
 
21. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 2010; 340:b5500.
http://dx.doi.org/10.1136/bmj.b5500
 
22. Engel P, Fagherazzi G, Boutten A, et al. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010; 19:2341-50.
http://dx.doi.org/10.1158/1055-9965.EPI-10-0264
 
23. Choo CS, Mamedov A, Chung M, et al. Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutr Res 2011; 31:21-6.
http://dx.doi.org/10.1016/j.nutres.2010.12.007
 
24. Heaney RP. Vitamin D: criteria for safety and efficacy. Nutr Rev 2008; 66:S178-81.
http://dx.doi.org/10.1111/j.1753-4887.2008.00102.x
 
25. Nowson CA, McGrath JJ, Ebeling PR, et al. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust 2012; 196:686-7.
http://dx.doi.org/10.5694/mja11.10301
 
26. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85:6-18.
PMid:17209171
 
27. Vieth R. Vitamin D and cancer mini-symposium: the risk of additional vitamin D. Ann Epidemiol 2009; 19:441-5.
http://dx.doi.org/10.1016/j.annepidem.2009.01.009
 
28. Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr 2006; 136:1117-22.
PMid:16549491
 
29. French D, Gorgi AW, Ihenetu KU, et al. Vitamin D status of county hospital patients assessed by the DiaSorin LIAISON® 25-hydroxyvitamin D assay. Clin Chim Acta 2011; 412:258-62.
http://dx.doi.org/10.1016/j.cca.2010.10.013
 
30. Bilinski K, Boyages S. The rise and rise of vitamin D testing. BMJ 2012; 345:e4743.
http://dx.doi.org/10.1136/bmj.e4743
 
31. Sattar N, Welsh P, Panarelli M, Forouhi NG. Increasing requests for vitamin D measurement: costly, confusing, and without credibility. Lancet 2012; 379:95-6.
http://dx.doi.org/10.1016/S0140-6736(11)61816-3
 
32. Kuriacose R, Olive KE. Prevalence of vitamin D deficiency and insufficiency in northeast Tennessee. South Med J 2008; 101:906-9.
http://dx.doi.org/10.1097/SMJ.0b013e318181881b
 
33. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106:963-8.
http://dx.doi.org/10.1016/j.amjcard.2010.05.027
 
34. Bang UC, Semb S, Nordgaard-Lassen I, Jensen JE. A descriptive cross-sectional study of the prevalence of 25-hydroxyvitamin D deficiency and association with bone markers in a hospitalized population. Nutr Res 2009; 29:671-5.
http://dx.doi.org/10.1016/j.nutres.2009.09.010
 
35. Hirani V, Tull K, Ali A, Mindell J. Urgent action needed to improve vitamin D status among older people in England! Age Ageing 2010; 39:62-8.
http://dx.doi.org/10.1093/ageing/afp195
PMid:19934073
 
36. Houghton LA, Szymlek-Gay EA, Gray AR, et al. Predictors of vitamin D status and its association with parathyroid hormone in young New Zealand children. Am J Clin Nutr 2010; 92:69-76.
http://dx.doi.org/10.3945/ajcn.2009.29055
 
37. Schoenmakers I, Ginty F, Jarjou LM, et al. Interrelation of parathyroid hormone and vitamin D metabolites in adolescents from the UK and The Gambia. J Steroid Biochem Mol Biol 2010; 121:217-20.
http://dx.doi.org/10.1016/j.jsbmb.2010.03.012
 
38. Napiórkowska L, Budlewski T, Jakubas-Kwiatkowska W, et al. Prevalence of low serum vitamin D concentration in an urban population of elderly women in Poland. Pol Arch Med Wewn 2009; 119:699-703.
PMid:19920793
 
39. Hochwald O, Harman-Boehm I, Castel H. Hypovitaminosis D among inpatients in a sunny country. Isr Med Assoc J 2004; 6:82-7.
PMid:14986463
 
40. Grant WB, Cross HS, Garland CF, et al. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol 2009; 99:104-13.
http://dx.doi.org/10.1016/j.pbiomolbio.2009.02.003
 
41. Grant WB, Schwalfenberg GK, Genuis SJ, Whiting SJ. An estimate of the economic burden and premature deaths due to vitamin D deficiency in Canada. Mol Nutr Food Res 2010; 54:1172-81.
PMid:20352622
 
42. Grant WB, Schuitemaker GE. Health benefits of higher serum 25-hydroxyvitamin D levels in The Netherlands. J Steroid Biochem Mol Biol 2010; 121:456-8.
http://dx.doi.org/10.1016/j.jsbmb.2010.03.089
 
43. Grant WB, Garland CF, Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem Photobiol 2005; 81:1276-86.
http://dx.doi.org/10.1562/2005-01-24-RA-424
 
44. Kaptein S, Risselada AJ, Boerma EC, Egbers PH, Nieboer P. Life-threatening complications of vitamin D intoxication due to over-the-counter supplements. Clin Toxicol (Phila) 2010; 48:460-2.
http://dx.doi.org/10.3109/15563650.2010.486382
 
45. Klontz KC, Acheson DW. Dietary supplement-induced vitamin D intoxication. N Engl J Med 2007; 357:308-9.
http://dx.doi.org/10.1056/NEJMc063341
 
46. Johnson MA, Davey A, Park S, Hausman DB, Poon LW; Georgia Centenarian Study. Age, race and season predict vitamin D status in African American and white octogenarians and centenarians. J Nutr Health Aging 2008; 12:690-5.
PMid:19043643 PMCid:PMC2978665
 
47. Lanske B, Razzaque MS. Vitamin D and aging: old concepts and new insights. J Nutr Biochem 2007; 18:771-7.
http://dx.doi.org/10.1016/j.jnutbio.2007.02.002
 
48. Bruyere O, Decock C, Delhez M, Collette J, Reginster JY. Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study. Womens Health (Lond Engl) 2009; 5:49-54.
http://dx.doi.org/10.2217/17455057.5.1.49
 
49. Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med J Aust 2006; 185:268-72.
PMid:16948623
 
50. Wolpowitz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it? J Am Acad Dermatol 2006; 54:301-17.
http://dx.doi.org/10.1016/j.jaad.2005.11.1057
 
51. Huotari A, Herzig KH. Vitamin D and living in northern latitudes--an endemic risk area for vitamin D deficiency. Int J Circumpolar Health 2008; 67:164-78.
http://dx.doi.org/10.3402/ijch.v67i2-3.18258
 
52. Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 2004; 19:752-8.
http://dx.doi.org/10.1359/jbmr.040125
 
53. Brustad M, Edvardsen K, Wilsgaard T, et al. Seasonality of UV-radiation and vitamin D status at 69 degrees north. Photochem Photobiol Sci 2007; 6:903-8.
http://dx.doi.org/10.1039/b702947k
 
54. Maeda SS, Kunii IS, Hayashi LF, Lazaretti-Castro M. Increases in summer serum 25-hydroxyvitamin D (25OHD) concentrations in elderly subjects in São Paulo, Brazil vary with age, gender and ethnicity. BMC Endocr Disord 2010; 10:12.
http://dx.doi.org/10.1186/1472-6823-10-12
 
55. Saliba W, Rennert HS, Kershenbaum A, Rennert G. Serum 25(OH)D concentrations in sunny Israel. Osteoporos Int 2012; 23:687-94.
http://dx.doi.org/10.1007/s00198-011-1597-y